Inaktiver Wert

Andere Sprachen Biofrontera AG OTC Markets

Aktien

Biofrontera Files Prospectus for Potential Secondary Stock Offerings	11.03.
Medicus Pharma Names COO	05.03.
BIOFRONTERA AG ANNOUNCES REVISED STRATEGY	21.02.
BIOFRONTERA AG, BIOFRONTERA TRANSFERS CLINICAL RESEARCH TO THE U.S.	21.02.
Biofrontera AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	28.11.
Earnings Flash (BFRI) BIOFRONTERA Reports Q3 Revenue $8.9M, vs. Street Est of $8.4M	09.11.
Biofrontera Licensor Gets FDA Approval for New Formulation of Ameluz to Treat Actinic Keratosis	10.10.23
Biofrontera Says Sun Pharmaceutical Alleging Breach of Contract In Lawsuit	03.10.23
Biofrontera AG Reports Earnings Results for the Half Year Ended June 30, 2023	31.08.23
Biofrontera Says Skin Disease Therapy Was Well-Tolerated in Phase 1 Safety Trial	28.08.23
Earnings Flash (BFRI) BIOFRONTERA Reports Q2 Revenue $5.8M	11.08.23
Biofrontera Completes Patient Enrollment in Skin Cancer Treatment Study	10.08.23
Top Premarket Decliners	21.07.23
Biofrontera Launches Novel Belixos Active Care	05.07.23
Biofrontera to Effect 1-for-20 Reverse Stock Split	03.07.23
Wall Street Set to Open Lower; Housing Starts Rise More Than Expected	20.06.23
Biofrontera AG Reports Earnings Results for the First Quarter Ended March 31, 2023	31.05.23
Biofrontera AG Completes Patient Recruitment of Ameluz Phase I Trial	17.05.23
Biofrontera Says it Obtained US Patent for New Photodynamic Therapy Protocol	15.05.23
Earnings Flash (BFRI) BIOFRONTERA Reports Q1 Revenue $8.7M, vs. Street Est of $9.2M	12.05.23

Keine Ergebnisse zu dieser Suche